SCOPE FLUIDICS S.A. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 169.8 PLN | -0.59% |
|
+2.29% | -13.37% |
| Sales 2021 | - | Sales 2022 | 404K 102K | Capitalization | 566M 143M |
|---|---|---|---|---|---|
| Net income 2021 | -16M -4.05M | Net income 2022 | 318M 80.45M | EV / Sales 2021 | - |
| Net cash position 2021 | 4.62M 1.17M | Net cash position 2022 | 329M 83.26M | EV / Sales 2022 | 585 x |
| P/E ratio 2021 |
-22
x | P/E ratio 2022 |
1.75
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
41.2% | Free-Float | 73.44% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.59% | ||
| 1 week | +2.29% | ||
| Current month | -0.59% | ||
| 1 month | +3.16% | ||
| 3 months | -19.14% | ||
| 6 months | -9.68% | ||
| Current year | -13.37% |
1 week
163.00
173.40
1 month
162.20204.50
Current year
162.00239.00
1 year
148.00239.00
3 years
83.00348.00
5 years
45.80348.00
10 years
9.55348.00
| Managers | Title | Age | Since |
|---|---|---|---|
Piotr Garstecki
CEO | Chief Executive Officer | 48 | 09-12-31 |
Marcin Izydorzak
FOU | Founder | 50 | 09-12-31 |
Szymon Ruta
DFI | Director of Finance/CFO | 48 | 16-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 49 | 17-03-06 | |
| Director/Board Member | 48 | 17-03-06 | |
| Founder | 61 | 09-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-03 | 169.8 | -0.59% | 169 |
| 24-05-31 | 170.8 | +1.67% | 481 |
| 24-05-29 | 168 | -0.24% | 2,218 |
| 24-05-28 | 168.4 | +1.45% | 1,532 |
| 24-05-27 | 166 | -7.26% | 11,597 |
Delayed Quote Warsaw S.E., June 03, 2024 at 06:58 am EDT
More quotes
Scope Fluidics SA is a Poland-based company engaged in the biotechnology. The Company focuses on diagnostic and med-tech solutions. It develops disposable microfluidic systems for the collection of micro-samples of blood, as well as storage of reagents for diagnostic markers. Its projects include PCR ONE system that delivers the bacterial and viral pathogen detection, and BacterOMIC system that delivers information on bacterial susceptibility to antibiotics and on the resistance mechanisms. The Company provides access to laboratories and workshops for developed projects, as well as administrative facilities and services, including financing. In addition, it cooperates with doctors, medical personnel, project managers, engineers and academics.
| 1st Jan change | Capi. | |
|---|---|---|
| -13.37% | 118M | |
| -38.56% | 8.39B | |
| +0.18% | 3.32B | |
| +9.29% | 2.48B | |
| -18.21% | 2.06B | |
| -24.57% | 1.59B | |
| +32.37% | 1.15B | |
| -7.64% | 704M | |
| +8.42% | 678M | |
| -29.59% | 508M |
- Stock Market
- Equities
- SCP Stock
